Macular Degeneration Trial, Recruiting NCT03921931 Sponsor: Medical University of Vienna Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT03921931
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older (men and women)
  • People who have signed a consent form agreeing to participate
  • People whose vision prescription (short-sightedness, long-sightedness, or astigmatism) is below 3 diopters
  • People who are able and willing to follow the study instructions

For healthy volunteers:

  • People with no eye conditions or abnormalities found during an eye examination

For people with Primary Open Angle Glaucoma (POAG):

  • People who have been diagnosed with a type of glaucoma called Primary Open Angle Glaucoma
  • People whose glaucoma has caused a level of vision field loss measured at 10 decibels (dB) or less (confirm with trial site)

For people with Age-Related Macular Degeneration (AMD):

  • People who have been diagnosed with the "dry" form of age-related macular degeneration
  • People whose dry AMD has been classified as Stage II or Stage III

Who may not be able to join:

  • People who have eye abnormalities that would prevent accurate measurements being taken
  • People who have eye inflammation or other eye conditions that could interfere with the study
  • People who have taken certain light-sensitive medications in the 3 months before the study (confirm which medications apply with the trial site)
  • People who have a condition that may cause sensitivity to light, including lupus (SLE), Porphyria, Vitiligo, Xeroderma Pigmentosum, or Albinism
  • People who have any form of epilepsy
  • People who have had eye surgery in the 3 months before the study
  • People who are pregnant, planning to become pregnant, or currently breastfeeding
  • People who have a serious ongoing or recent medical or surgical illness or disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Doreen Schmidl, MD,PhD, Department of Clinical Pharmacology, Medical University of Vienna

Phone: 0043140400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
26 November 2018
Est. completion
31 May 2026

Where this trial is recruiting

🇦🇹 Austria

Primary endpoints

Light stimulation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov